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Case Report
Case of Inhaled Prostaglandin E1 used to improve Hypoxia in ARDS
Shahla Siddiqui, Salwa Zubair*, F. Hameed Khan
Departments of Anesthesiology and Pharmacy*, Aga Khan University Hospital, Karachi.

Introduction
The 'adult respiratory distress syndrome', or ARDS,
is a term used to describe the sudden onset of acute respiratory failure characterized by pulmonary edema arising from
increased lung permeability.1 By definition four essential
components should be present: 1) chest X-ray evidence of
bilateral infiltrates, 2) exclusion of heart failure, by a wedge
of less than 20 mm HG or clinical examination, 3) underlying disease and 4) severe hypoxemia with a PaO2 / FiO2
ratio of < 200. ARDS is a physiologic syndrome, not a single disease which results in a ventilation- perfusion (v/q)
mismatch within the lung due to areas of poor ventilation.
As a result of the progressive hypoxemia, pulmonary vascular resistance also rises and can lead to right ventricular failure.1,2
The clinical syndrome is a common pathway resulting from a wide variety of insults, which can be intra- or
extra-pulmonary. Although it has been a well-known entity
since the 'shock-lung' patients seen in the Vietnam war in
1967, the mortality still remains high.3 Many therapeutic
modalities have been used, but no single treatment measure
has shown significant improvement in mortality. These
include recruitment maneuvers, prone positioning, high
PEEP, low tidal volumes, inverse ratio ventilation and
inhaled nitric oxide.4
In the last few years, prostaglandins have been
experimentally used via inhalation, in order to improve perfusion selectively in the well ventilated areas of the lung.
This reduces the V/Q mismatch and shunt, hereby improving oxygenation.5 Blood is thus diverted from areas of collapse to the well- ventilated ones. Studies suggest that in
ARDS, inhalation of aerosolized PGE1 (a breakdown product of arachidonic acid with vasodilating properties) and
nitric oxide (NO) in low concentrations equally improve
pulmonary vascular resistance and gas exchange. NO is
much more expensive and associated with several complications. PGE1 has also shown reduction in cytokine mediated alveolar cell injury. Previous studies indicated that
PGE1 disaggregates platelets and reduces local vasoconstriction in the pulmonary circulation.6

Case Report
A 6 year old (FK), known case of acute lymphocytic leukemia (ALL) was admitted with cough for 1 week and
shortness of breath for 1 day prior to presentation. Informed

Table. Arterial Blood gases before and after PGE1 nebulisation.
Day 10

Without PGE1

Ventilator
settings

AM Arterial blood gas

PM arterial blood gas

Pressure control 18

pH 7.31

pH 7.32

Respiratory Rate 35

PaCO2 65

PCO2 56

Peep 15

PaO2 49

PaO2 53

FiO2 1.0

HCO3 33

HCO3 30

Base excess 5

BE 3

Saturation 79%

Saturation 84%

Day 11

First dose of PGE1

Three doses of PGE1

Ventilator

AM arterial blood gases

PM blood gases

Pressure control 16

pH 7.29

pH 7.22

Respiratory Rate 39

PaCO2 53

PaCO2 78

setting

Peep 15

PaO2 103

PaO2 86

FiO2 1.0

HCO3 24

HCO3 32

BE -2

BE 3

Saturation 96%

Saturation 93%

Day 12

5 doses of PGE1

8 doses of PGE1

Ventilator

AM arterial blood gases

PM arterial blood gases

PC 16

pH 7.30

pH 7.3

RR 39

PaCO2 59

PaCO2 67

settings

Peep 15

PaO2 61

PaO2 56

FiO2 1.0

HCO3 32

HCO3 35

BE 5

BE 7.5

Saturation 86%

Saturation 85%

consent was obtained from the family. He was admitted
with a diagnosis of pneumonia based on chest X Ray findings and clinical picture. After two days he required intubation and ICU admission for progressive hypoxemia and
bilateral diffuse infiltrates on CXR, in keeping with ARDS.
He was sedated and relaxed for his worsening status requiring maximal ventilatory support. He was also started on
clarithromycin, Septran and meropenem. On the fourth day,
when despite a ventilatory support of 1.0 FiO2 and pressure
control ventilation with a peep of 15 cm H2O, his PaO2 did
not improve more than 49 mmHg (Alveolar - arterial gradi-

arterial gradient of 450 mmHg), he was placed in a
prone position7 for eight hours / day. He was also started on
high dose IV methylprednisolone7,8 in accordance with
management of ARDS, on day 6. However, his respiratory
acidosis and hypoxia continued. His chest Xray continued
to show a diffuse ground glass appearance.
On day 10, Alprostadil (PGE1)9,10 was nebulised
over 30 minutes every six hours. The dose used was 5
mcgs. in normal saline. Over the next 12-24 hours a
marked improvement in oxygenation was seen on his arterial blood gases (Table). His A-a gradient improved, however, his CXR remained unchanged. No other parameter (proning, ventilatory support, antibiotics) was changed during the
therapy. This improvement in PaO2 was not sustained and
drifted down once again, despite increasing the PGE1 nebulisation frequency. He died on day 13 of admission following a bradycardic arrest and worsening sepsis.

Discussion
Alprostadil (PGE1) is a product of the arachidonic
acid metabolism and causes vasodilation by increasing
camp.11 Intractable respiratory failure and hypoxemia leading to multi organ failure in ARDS patient remains a difficult to manage problem for most intensivists. It also presents a huge burden on health care costs. Although many
strategies have been proposed and research is ongoing for
finding remedies for this illness, no single therapy or
maneuver has improved outcome or mortality. Inhaled
vasodilators that affect the pulmonary vasculature selectively (i.e. only the perfusion of areas well ventilated) are
appealing adjuncts in many cardiopulmonary conditions
that require mechanical ventilation such as ARDS, COPD
and Primary pulmonary hypertension.12 Inhaled nitric
oxide (NO) and aerosolized prostaglandins like PGE1 offer
advantage of selective pulmonary vasodilation with minimal systemic effects.13 Both agents decrease peak airway

pressures (PAP), pulmonary vascular resistance (PVR) and
in many cases improve oxygenation acutely; however, the
effect has not led to improved long-term outcomes. Nitric
oxide, besides being expensive and not readily available,
has systemic side effects.14,15 Currently, their use remains
investigational and no large randomised controlled trials
have been done to see the efficacy.
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